EUVIMEDEUVIMED entdecken
Crossref

Pan-cancer characterization of the pyrimidine catabolic enzyme UPB1 identifies a tumor-suppressive prognostic biomarker in skin cutaneous melanoma

Yingli Men, Yi Shao, Yongfeng Chen, Ping Wang, Yiyang Li, Zhenzhen Yang, Ruiting Feng, Hui Wang, Yinsen Song, Cong Ding

Naunyn-Schmiedeberg's Archives of Pharmacology · 2026

DOI: 10.1007/s00210-026-05716-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2026. Verfasst von Yingli Men und 9 weiteren Autor:innen. Beteiligte Einrichtung: Translational Medicine Research Center, The Fifth Clinical Medical College of Henan University of Chinese Medicine (Zhengzhou People's Hospital), 33 …. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms, Biomarkers, Tumor, Pyrimidines. Die Arbeit nennt 44 Literaturangaben. Gefördert von: the project of scientific and technological innovation guidance program in the medical and health field of Zhengzhou, the Henan province science and technology research project, the 2628 talent enhancement project - three heroes talent program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic reprogramming of pyrimidine metabolism contributes to tumor progression; however, the oncological role of beta-ureidopropionase 1 (UPB1), the terminal enzyme in pyrimidine catabolism, remains poorly understood. This study aimed to characterize the expression profile, prognostic value, molecular alterations, immune associations, and functional significance of UPB1 across multiple cancer types, with focused validation in skin cutaneous melanoma (SKCM). UPB1 expression and its clinical relevance were evaluated using TCGA-based pan-cancer datasets and integrated bioinformatics platforms, including SangerBox, TIMER 2.0, GEPIA2, UALCAN, GSCA, cBioPortal, and LinkedOmics. Its functional effects were assessed in SK-MEL-2 and A375 melanoma cells using UPB1 overexpression, proliferation and migration assays, and Western blot analysis of epithelial-mesenchymal transition markers. UPB1 was significantly downregulated in multiple tumor types, including SKCM. Reduced UPB1 expression was associated with advanced clinicopathological features and poorer overall survival, disease-free survival, and progression-free interval in several malignancies. Genetic analyses revealed predominantly missense mutations, with the highest alteration frequency observed in SKCM, as well as tumor-specific differences in promoter methylation. UPB1 expression was positively associated with the infiltration of effector immune cells and the expression of key immunomodulatory molecules. In melanoma cells, UPB1 overexpression inhibited proliferation and migration and suppressed epithelial-mesenchymal transition, as evidenced by increased E-cadherin expression and decreased N-cadherin and vimentin expression. Collectively, these findings suggest that UPB1 functions as a tumor-suppressive factor linked to pyrimidine catabolism and may serve as a prognostic biomarker, particularly in SKCM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaSkin NeoplasmsBiomarkers, TumorPyrimidinesHumansCutaneous Malignant MelanomaCell Line, TumorPrognosisCell ProliferationEpithelial-Mesenchymal TransitionCell MovementGene Expression Regulation, NeoplasticFemale

Stichwörter der Autor:innen

Pan-cancerSkin cutaneous melanomaUPB1

Substanzen

Biomarkers, TumorPyrimidines

Autor:innen und Institutionen

  • Translational Medicine Research Center, The Fifth Clinical Medical College of Henan University of Chinese Medicine (Zhengzhou People's Hospital), 33 Huanghe Road, Zhengzhou, 450002, Henan, China.
  • Dermatology Department, Henan Provincial People's Hospital, Zhengzhou, Henan, China.
  • Information Department, Henan Cancer Hospital, Zhengzhou, Henan, China.
  • Translational Medicine Research Center, The Fifth Clinical Medical College of Henan University of Chinese Medicine (Zhengzhou People's Hospital), 33 Huanghe Road, Zhengzhou, 450002, Henan, China. df13607670608@163.com.
  • Respiratory and Immune Diseases Laboratory, Children's Hospital Affiliated to Zhengzhou University, 33 Longhu Waihuan East Road, Zhengzhou, Henan, 450018, P.R. China. dingcong8866@163.com.

Förderung

  • the project of scientific and technological innovation guidance program in the medical and health field of Zhengzhou
  • the Henan province science and technology research project
  • the 2628 talent enhancement project - three heroes talent program

Zitieren

APA

Men, Y., Shao, Y., Chen, Y., Wang, P., Li, Y., Yang, Z., Feng, R., Wang, H., Song, Y., & Ding, C. (2026). Pan-cancer characterization of the pyrimidine catabolic enzyme UPB1 identifies a tumor-suppressive prognostic biomarker in skin cutaneous melanoma. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-026-05716-9

Vancouver

Men Y, Shao Y, Chen Y, Wang P, Li Y, Yang Z, et al. Pan-cancer characterization of the pyrimidine catabolic enzyme UPB1 identifies a tumor-suppressive prognostic biomarker in skin cutaneous melanoma. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026. doi:10.1007/s00210-026-05716-9

BibTeX
@article{Men2026,
  author = {Men, Yingli and Shao, Yi and Chen, Yongfeng and Wang, Ping and Li, Yiyang and Yang, Zhenzhen and Feng, Ruiting and Wang, Hui and Song, Yinsen and Ding, Cong},
  title = {Pan-cancer characterization of the pyrimidine catabolic enzyme UPB1 identifies a tumor-suppressive prognostic biomarker in skin cutaneous melanoma},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2026},
  doi = {10.1007/s00210-026-05716-9}
}
Kostenlos starten →